The Teva rep she quoted said both facilities had been inspected. By "both" I take it to mean that the suppliers facilities were also inspected. I obviously was not there to hear how Ms. Chen actually asked the question of the Teva rep. Perhaps, if one of the other analysts asks this in a public forum, there will be no questions about what was asked, and can trust the answer that much more. I took some time to compose my questions so that both Teva's facilities and those of their suppliers were the subjects, and tried to leave as little wiggle room as possible. If Ms. Chen did not paraphrase my questions too much when putting them to the Teva rep, then I think we have to assume both Teva's facilities and those of their suppliers have both been inspected and have probably passed. But note the word "passed" doesn't actually show up in the reply.
So it is possible they were both inspected, the suppliers did not pass, and there will have to be another one for the supplier. But I assign a fairly low probability to that case. I imagine, since the heparin scare, that the suppliers have really made an effort to get their act together.
Market Data 
Markets 
AI
